Here is the design of a clinical trial:

Official Title: A Randomized Double-blind, Placebo-controlled, Multi-center Trial to Investigate the Efficacy and Safety of NeuroAiD II™ (MLC901) to Improve Cognitive Functioning in Non-surgical Mild Traumatic Brain Injury Patients

Included conditions:
- Traumatic Brain Injury

Study Armgroups:
- {'label': 'NeuroAiD II™ (MLC901)', 'type': 'ACTIVE_COMPARATOR', 'description': 'Recommended treatment is 2 capsules orally, 3 times a day (i.e. 6 capsules per day). Treatment is 12 weeks.', 'interventionNames': ['Combination Product: Traditional Chinese Medicine (NeuroAiD II™ (MLC901)']}
- {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Capsule 2 capsules orally, 3 times a day', 'interventionNames': ['Other: Placebo']}

Interventions:
- {'type': 'COMBINATION_PRODUCT', 'name': 'Traditional Chinese Medicine (NeuroAiD II™ (MLC901)', 'description': "NeuroAiD II™ (MLC901) contains the extracts of 9 botanical active ingredients blended with commonly used excipients. The 9 botanical active ingredients are traditional herbs well documented in the Pharmacopoeia of the People's Republic of China.", 'armGroupLabels': ['NeuroAiD II™ (MLC901)']}
- {'type': 'OTHER', 'name': 'Placebo', 'description': 'Placebo with same appearance as active intervention', 'armGroupLabels': ['Placebo']}

Primary Outcomes:
- {'measure': 'Central Nervous System Vital Signs (CNS-VS), Domain score: Complex Attention', 'description': 'Change in complex attention score, determined using Central Nervous System Vital Signs (CNS-VS) computer cognitive testing system, after 6 months of treatment compared to baseline in the group of patients receiving NeuroAiD II™ (MLC901), compared to the placebo group.\n\nIn the domain dashboard, above average domain scores indicate a Standard Score (SS) greater than 109 or a Percentile Rank (PR) greater than 74, indicating a high functioning test subject. Average is a SS 90-102 or PR 25-74, indicating normal function. Low average is SS 80-99 or PR 9-24 indicating a slight deficit or impairment. Below average is SS 70-79 or PR 2-8, indicating moderate level of deficit or impairment. Very low is SS less than 70 or a PR less than 2, indicating a deficit and impairment. Lower score is better for Complex Attention.', 'timeFrame': '6 months of treatment compared to baseline'}

Please estimate the sample size based on the assumption: 
Target power: 80%. Two-sided significance level: 5%. Hypotheses: H0: MT≥MR, H1: MT<MR. The sample size is increased to allow for 30% dropouts.
Sample size consideration
        An estimate of 20 for SD of change in complex attention from baseline to 6 months was obtained from the BRAINS pilot study of MLC901 in 78 patients with mild or moderate TBI.26 A minimally clinically meaningful difference of â10 in the mean change in complex attention, using CNS-VS, per group was determined. Target power: 80%. Two-sided significance level: 5%. The proportion of subjects in groups 1:1. Hypotheses: H0: MTâ¥MR, H1: MT<MR, where MT is an arithmetical mean of change of complex attention score after 6 months of treatment, compared with baseline, in the MLC901 group, and MR is an arithmetical mean of change from baseline of complex attention score after 6 months of treatment in the placebo group (lower score of complex attention is better). One hundred and twenty eight subjects are required to detect a clinically meaningful difference of â10 in the mean changes in complex attention between MLC901 and placebo arms with 80% power at a two-sided 5% significance level. The sample size is increased to 182 subjects (91 per arm) to allow for 30% dropouts.